Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | BLM | P54132 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.53 |
| ▸ | CASP7 | P55210 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31214551 | 0.81 | MAPT (0.62) | KDM4EALDH1A1BLMTDP1CASP7 | |
| SCHEMBL7833902 | 0.76 | KDM4E (0.55) | KDM4EALDH1A1BLMTDP1CASP7 | |
| SCHEMBL3261597 | 0.75 | KDM4E (0.46) | KDM4EALDH1A1BLMTDP1CASP7 | |
| Lumichrome SCHEMBL29516827 | 0.75 | BLM (0.64) | KDM4EALDH1A1BLMTDP1CASP7 | |
| Lumichrome SCHEMBL194906 | 0.75 | BLM (0.64) | KDM4EALDH1A1BLMTDP1CASP7 | |
| Lumichrome SCHEMBL29861572 | 0.75 | BLM (0.64) | KDM4EALDH1A1BLMTDP1CASP7 | |
| SCHEMBL5309140 | 0.72 | KDM4E (0.53) | KDM4EALDH1A1BLMTDP1CASP7 | |
| SCHEMBL7822136 | 0.72 | BLM (0.47) | KDM4EALDH1A1BLMTDP1CASP7 | |
| SCHEMBL34472892 | 0.71 | L3MBTL1 (0.39) | KDM4EALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL4320247 | 0.70 | KDM4E (0.57) | KDM4EALDH1A1BLMTDP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226065-A1 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | COMVITA LIMITED (NZ) | 2023-07-20 | — | — | US | disclosed |
| US-20230226065-A1 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | COMVITA LIMITED (NZ) | 2023-07-20 | — | — | US | disclosed |
| WO-2022005308-A1 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | COMVITA LIMITED (NZ) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021002763-A1 | USE OF A COMPOSITION COMPRISING 3,6,7-TRIMETHYLLUMAZINE FOR PREVENTING, AMELIORATING OR TREATING MMP-9 ASSOCIATED CONDITIONS AND INFLAMMATION | COMVITA LIMITED (NZ) | 2021-01-07 | — | — | WO | disclosed |
| WO-2017099612-A1 | MARKER COMPOUNDS OF LEPTOSPERMUM HONEYS AND METHODS OF ISOLATION AND ASSAYING THEREOF | COMVITA LIMITED (NZ) | 2017-06-15 | — | — | WO | disclosed |
| EP-0759927-B1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | US GOV HEALTH & HUMAN SERV (US) | 1998-06-24 | — | — | EP | disclosed |
| US-5612468-A | GENETIC ENGINEERING | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-18 | — | — | US | disclosed |
| EP-0759927-A1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5525711-A | MONOMERS FOR DNA AMPLIFICATION PROCEDURES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1995031469-A1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-11-23 | — | — | WO | disclosed |
| EP-0071903-B1 | DIGLYCIDYL PTERIDINE COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN DRUGS WITH A CYTOSTATIC ACTIVITY | Henkel Kommanditgesellschaft auf Aktien (DE) | 1985-08-28 | — | — | EP | disclosed |
| US-4463006-A | ANTICANCER, ANTITUMOR AGENTS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1984-07-31 | — | — | US | disclosed |
| EP-0071903-A1 | Diglycidyl pteridine compounds, method for their preparation and their use in drugs with a cytostatic activity | Henkel Kommanditgesellschaft auf Aktien (DE) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226065-A1 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | PTGES2, TPMT, PARK7 | KDM4E 3316/4885ALDH1A1 2288/4885BLM 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.